Portal de Periódicos da CAPES

Comparative Study of Muromonab-CD3 (OKT3) Versus Daclizumab (Zenapax) in Cardiac Transplantation at Our Center

2005; Elsevier BV; Volume: 37; Issue: 3 Linguagem: Inglês

10.1016/j.transproceed.2005.02.023

1873-2623

Ana Campos, E. Lage, R. Hinojosa, Antonio Ordóñez, José Miguel Cisneros, Soledad Cabezón, Sílvia Gómez, A. Aguilera, Eduardo Arana‐Rueda, Aurelio Cayuela,

Viral Infections and Immunology Research

Recent studies support the addition of new immunosuppressive drugs as cytolytic induction therapy in cardiac transplantation. We carried out a comparative study comprising 52 patients who had undergone cardiac transplantation at our center. Thirty patients received muromonab-CD3 (OKT3, Janssen-Cilag, The Netherlands) as the induction therapy, whereas 22 patients received Daclizumab (Zenapax, Hoffman-La Roche, Nutley, NJ, USA) instead. All patients received cyclosporine or tacrolimus, mycophenolate, and steroids. Over an average follow-up period of 23.21 ± 18 months, we analyzed retrospectively the incidence of grade ≥3A biopsy-confirmed acute rejection episodes, the presence of infectious processes at 1 and 6 months, the occurrence of significant secondary effects, and the necessity to modify the immunosuppressive therapy during the follow-up. The results suggest that daclizumab is linked to a decreased incidence of grade ≥3A biopsy-confirmed acute rejection and to a reduced necessity to modify the immunosuppressive therapy during the medium-term follow-up.